Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

UFT (uracil and tegafur in a 4:1 molar ratio) plus calcium folinate treatment has favorable activity and tolerable toxicity in patients with advanced gastric carcinoma. High response rates have been reported in patients with advanced gastric carcinoma receiving a schedule of epirubicin, cisplatin (Platinol), and protracted infusion of 5-fluorouracil (5-FU). Replacing the inconvenient infusion pump and intravenous catheter needed for protracted infusion of 5-FU, we administered oral UFT plus calcium folinate (Orzel) to 37 patients (median age, 55 years; median World Health Organization [WHO] performance status of 1) with locally advanced or metastatic gastric carcinoma. Epirubicin 50 mg/m2 and cisplatin 60 mg/m2 were administered by intravenous injection on day 1; UFT 360 mg/m2/day po was administered in conjunction with oral calcium folinate 25 mg/m2/day in divided daily doses for 21 days, followed by a 7-day rest period. Courses were repeated every 4 weeks. Among 37 evaluable patients who received a median of four courses of treatment (range, 2 to 10), two achieved a complete response and 18 a partial response, for an overall response rate of 54% (95% confidence interval, 39% to 70%). Stable disease was reported in 12 patients (32.4%) and disease progression in another five (13.5%). The median duration of survival was 10 months (range, 2 to 15+). The main toxicities were nausea/vomiting, leukopenia, diarrhea, and oral mucositis. WHO grade 3 or 4 toxicity included leukopenia in 14 patients (37.8%), nausea/vomiting in 11 (29.7%), oral mucositis in five (13.5%), and diarrhea in four (10.8%). Epirubicin, cisplatin, and oral UFT plus calcium folinate, a convenient outpatient regimen, has significant activity and tolerable toxicities in patients with gastric carcinoma.

Original languageEnglish
Pages (from-to)64-68
Number of pages5
JournalOncology
Volume13
Issue number7 SUPPL.
Publication statusPublished - 1999 Aug 20

Fingerprint

Epirubicin
Leucovorin
Cisplatin
Stomach
Carcinoma
Stomatitis
Leukopenia
Fluorouracil
Nausea
Vomiting
Diarrhea
Tegafur
Infusion Pumps
Uracil
Intravenous Injections
Disease Progression
Appointments and Schedules
Outpatients
Catheters
Confidence Intervals

ASJC Scopus subject areas

  • Oncology

Cite this

Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma. / Kim, Yeul Hong; Kim, Byung Soo; Seo, Jae Hong; Choi, Chul Won; Kim, Jae Seon; Chun, Hoon-Jai; Hyun, Jin Hai; Kim, Jun Suk.

In: Oncology, Vol. 13, No. 7 SUPPL., 20.08.1999, p. 64-68.

Research output: Contribution to journalArticle

@article{02cd288013f34fa48d4f8f1c4341c15b,
title = "Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma",
abstract = "UFT (uracil and tegafur in a 4:1 molar ratio) plus calcium folinate treatment has favorable activity and tolerable toxicity in patients with advanced gastric carcinoma. High response rates have been reported in patients with advanced gastric carcinoma receiving a schedule of epirubicin, cisplatin (Platinol), and protracted infusion of 5-fluorouracil (5-FU). Replacing the inconvenient infusion pump and intravenous catheter needed for protracted infusion of 5-FU, we administered oral UFT plus calcium folinate (Orzel) to 37 patients (median age, 55 years; median World Health Organization [WHO] performance status of 1) with locally advanced or metastatic gastric carcinoma. Epirubicin 50 mg/m2 and cisplatin 60 mg/m2 were administered by intravenous injection on day 1; UFT 360 mg/m2/day po was administered in conjunction with oral calcium folinate 25 mg/m2/day in divided daily doses for 21 days, followed by a 7-day rest period. Courses were repeated every 4 weeks. Among 37 evaluable patients who received a median of four courses of treatment (range, 2 to 10), two achieved a complete response and 18 a partial response, for an overall response rate of 54{\%} (95{\%} confidence interval, 39{\%} to 70{\%}). Stable disease was reported in 12 patients (32.4{\%}) and disease progression in another five (13.5{\%}). The median duration of survival was 10 months (range, 2 to 15+). The main toxicities were nausea/vomiting, leukopenia, diarrhea, and oral mucositis. WHO grade 3 or 4 toxicity included leukopenia in 14 patients (37.8{\%}), nausea/vomiting in 11 (29.7{\%}), oral mucositis in five (13.5{\%}), and diarrhea in four (10.8{\%}). Epirubicin, cisplatin, and oral UFT plus calcium folinate, a convenient outpatient regimen, has significant activity and tolerable toxicities in patients with gastric carcinoma.",
author = "Kim, {Yeul Hong} and Kim, {Byung Soo} and Seo, {Jae Hong} and Choi, {Chul Won} and Kim, {Jae Seon} and Hoon-Jai Chun and Hyun, {Jin Hai} and Kim, {Jun Suk}",
year = "1999",
month = "8",
day = "20",
language = "English",
volume = "13",
pages = "64--68",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "7 SUPPL.",

}

TY - JOUR

T1 - Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma

AU - Kim, Yeul Hong

AU - Kim, Byung Soo

AU - Seo, Jae Hong

AU - Choi, Chul Won

AU - Kim, Jae Seon

AU - Chun, Hoon-Jai

AU - Hyun, Jin Hai

AU - Kim, Jun Suk

PY - 1999/8/20

Y1 - 1999/8/20

N2 - UFT (uracil and tegafur in a 4:1 molar ratio) plus calcium folinate treatment has favorable activity and tolerable toxicity in patients with advanced gastric carcinoma. High response rates have been reported in patients with advanced gastric carcinoma receiving a schedule of epirubicin, cisplatin (Platinol), and protracted infusion of 5-fluorouracil (5-FU). Replacing the inconvenient infusion pump and intravenous catheter needed for protracted infusion of 5-FU, we administered oral UFT plus calcium folinate (Orzel) to 37 patients (median age, 55 years; median World Health Organization [WHO] performance status of 1) with locally advanced or metastatic gastric carcinoma. Epirubicin 50 mg/m2 and cisplatin 60 mg/m2 were administered by intravenous injection on day 1; UFT 360 mg/m2/day po was administered in conjunction with oral calcium folinate 25 mg/m2/day in divided daily doses for 21 days, followed by a 7-day rest period. Courses were repeated every 4 weeks. Among 37 evaluable patients who received a median of four courses of treatment (range, 2 to 10), two achieved a complete response and 18 a partial response, for an overall response rate of 54% (95% confidence interval, 39% to 70%). Stable disease was reported in 12 patients (32.4%) and disease progression in another five (13.5%). The median duration of survival was 10 months (range, 2 to 15+). The main toxicities were nausea/vomiting, leukopenia, diarrhea, and oral mucositis. WHO grade 3 or 4 toxicity included leukopenia in 14 patients (37.8%), nausea/vomiting in 11 (29.7%), oral mucositis in five (13.5%), and diarrhea in four (10.8%). Epirubicin, cisplatin, and oral UFT plus calcium folinate, a convenient outpatient regimen, has significant activity and tolerable toxicities in patients with gastric carcinoma.

AB - UFT (uracil and tegafur in a 4:1 molar ratio) plus calcium folinate treatment has favorable activity and tolerable toxicity in patients with advanced gastric carcinoma. High response rates have been reported in patients with advanced gastric carcinoma receiving a schedule of epirubicin, cisplatin (Platinol), and protracted infusion of 5-fluorouracil (5-FU). Replacing the inconvenient infusion pump and intravenous catheter needed for protracted infusion of 5-FU, we administered oral UFT plus calcium folinate (Orzel) to 37 patients (median age, 55 years; median World Health Organization [WHO] performance status of 1) with locally advanced or metastatic gastric carcinoma. Epirubicin 50 mg/m2 and cisplatin 60 mg/m2 were administered by intravenous injection on day 1; UFT 360 mg/m2/day po was administered in conjunction with oral calcium folinate 25 mg/m2/day in divided daily doses for 21 days, followed by a 7-day rest period. Courses were repeated every 4 weeks. Among 37 evaluable patients who received a median of four courses of treatment (range, 2 to 10), two achieved a complete response and 18 a partial response, for an overall response rate of 54% (95% confidence interval, 39% to 70%). Stable disease was reported in 12 patients (32.4%) and disease progression in another five (13.5%). The median duration of survival was 10 months (range, 2 to 15+). The main toxicities were nausea/vomiting, leukopenia, diarrhea, and oral mucositis. WHO grade 3 or 4 toxicity included leukopenia in 14 patients (37.8%), nausea/vomiting in 11 (29.7%), oral mucositis in five (13.5%), and diarrhea in four (10.8%). Epirubicin, cisplatin, and oral UFT plus calcium folinate, a convenient outpatient regimen, has significant activity and tolerable toxicities in patients with gastric carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0011550492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0011550492&partnerID=8YFLogxK

M3 - Article

C2 - 10442365

AN - SCOPUS:0011550492

VL - 13

SP - 64

EP - 68

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 7 SUPPL.

ER -